Avian leukosis virus (ALV)-free candidate primary and secondary seed lots were indistinguishable from corresponding ALV-contaminated lots with respect to (i) potency as measured by titration in newborn and weanling mice and in the MA-104 plaque system, (ii) degree of viscerotropism as measured by viremia in monkeys, (iii) neurotropism as determined by the monkey neurovirulence test, and (iv) potency as determined by antibody response in monkeys inoculated by the intracerebral route.
The development of avian leukosis virus (ALV)-free primary and secondary yellow fever (YF) vaccine seed lots was described in an earlier paper (7) . This report deals with our evaluation of ALV-free seed lots with respect to neurovirulence characteristics, development of viremia, and antibody production in monkeys inoculated by the intracerebral route. A comparison is made with similar tests performed with ALV-contaminated seed lots.
MATERLALS AND METHODS Vaccines. Four different lots of 17D YF vaccine were used. Lot AB-237 and lot 5731 were the ALVcontaminated primary and secondary seed lots, respectively; lots 17D-51 and 6676 (prepared by National Drug Co. under contract by the Division of Biologics Standards) were the ALV-free candidate primary and secondary seed lots, respectively.
Viruses. Infectious stock YF virus (17D strain) used in the plaque neutralization (PN) and in some of the mouse neutralization (MN) tests was made from suckling mouse (SM) brains harvested when animals sickened and was prepared as a 20% suspension in phosphate-buffered saline (1) with 0.5% bovine plasma albumin. The 17D vaccine strain was passaged three times in 10-to 12-g mice and four times in SM in the Laboratory of Virology and Rickettsiology (LVR).
The French neurotropic (FN) strain of YF virus used in some of the MN tests was made from brains of mice (20 to 22 g) harvested when the animals were paralyzed, and was prepared as a 15% suspension in chicken embryo fluid in the routine manner followed in the Laboratory of Control Activities (LCA (6) . The difference in titer between serum samples taken before and 28 days after YF vaccine inoculation represents the neutralizing capacity of the serum and is expressed as neutralization index (NI) in this paper.
MN tests. MN tests performed in one of our laboratories (LVR) were previously described (6) and will be identified as LVR tests in this paper. In these tests, deaths occurring over a period of 21 days were recorded; LDso end points were determined by the Kdrber method (4) and expressed as decimal exponent (Dex) values (3) .
MN tests performed in another of our laboratories (LCA) utilized samples of the same sera tested in LVR. However, the FN strain of YF was used according to the procedure described in the international requirements for YF vaccine (8) .
Monkey neurovirulence test. Twenty-four monkeys were used in each of two comparative neurovirulence tests performed as prescribed in the international requirements. In the first test, 12 monkeys were inoculated with 0.25 ml of the ALV-contaminated primary YF vaccine seed (lot AB-237) by the intracerebral route (into the frontal cortex) and 12 received the ALV-free YF vaccine primary seed candidate (lot 17D-51) inoculated similarly. In the second test, 12 monkeys were inoculated with an ALVcontaminated secondary seed (ot 5731) and 12 received the ALV-free candidate secondary seed (lot 6676). (Tables 2 and 3 ). The data in Table 3 ary seed lots developed such signs. However, all of appear to indicate that the antibody titers obthe monkeys had histological evidence of encepha-tained by use 
